Precursor Cell Lymphoblastic Leukemia-Lymphoma clinical trials

The registry lists 2,584 studies for Precursor Cell Lymphoblastic Leukemia-Lymphoma across more than 10 countries. 473 are recruiting or about to start. 1,224 of them are mainly about Precursor Cell Lymphoblastic Leukemia-Lymphoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Precursor T-Cell Lymphoblastic Leukemia-Lymphoma: 2,763 studies, 531 open.

ClinicalTrials.gov finds 2,966 studies for Precursor Cell Lymphoblastic Leukemia-Lymphoma. How that becomes 2,584 here

This page counts the studies the registry files under Precursor Cell Lymphoblastic Leukemia-Lymphoma, and those it files under no condition that list Precursor Cell Lymphoblastic Leukemia-Lymphomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

2,966Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−179Filed under a narrower condition, counted on its own pagePrecursor T-Cell Lymphoblastic Leukemia-Lymphoma 160 · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 18
−211List Precursor Cell Lymphoblastic Leukemia-Lymphoma as a condition, but the registry did not file them under itMost often written as “B-cell Acute Lymphoblastic Leukemia” (83), “B Acute Lymphoblastic Leukemia” (21), and “Recurrent B Acute Lymphoblastic Leukemia” (16). The registry filed them under other conditions only, most often Burkitt Lymphoma (178) and Recurrence (33).
−47Match it another way30 name it in the title, 14 in a keyword, and 3 by a synonym or other text the search reads.
2,529Counted here and found by its search7 of them list Precursor Cell Lymphoblastic Leukemia-Lymphoma in their own words; the registry filed them under no condition.
+55
Counted here, but its search does not find them
The first 20 of 55.
2,584The count on this page

Get an email when these change. Save the Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,307
Recruiting: 370
Terminated: 298
Status unknown: 240
Active, not recruiting: 152
Withdrawn: 93

Phase

Phase 2: 926
Phase 1: 855
Phase 3: 203
Phase 4: 63
Early Phase 1: 41

Where

United States: 1,544
China: 232
Canada: 172
France: 152
Italy: 148
Germany: 130

Who runs them

National Cancer Institute (NCI) (152) · Fred Hutchinson Cancer Center (95) · M.D. Anderson Cancer Center (88) · Children's Oncology Group (73) · St. Jude Children's Research Hospital (70) · City of Hope Medical Center (55) · Memorial Sloan Kettering Cancer Center (46) · Masonic Cancer Center, University of Minnesota (45)

What is being tested here

Drugs under test in Precursor Cell Lymphoblastic Leukemia-Lymphoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	25	17	182
Fludarabine	22	6	134
Blinatumomab	19	12	54
Venetoclax	13	3	24
Cytarabine	8	15	85
Dexamethasone	8	13	58
Busulfan	7	5	73
Melphalan	7	3	58
Inotuzumab Ozogamicin	7	1	19
Olverembatinib	7	2	7

Drug classes tested here Alkylating agents 35 open · Antimetabolites 34 open · Tyrosine kinase inhibitors (TKIs) 24 open · Corticosteroids 11 open · Antibody-drug conjugates (ADCs) 7 open

Coming up

39phase 3 studies under way

165studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents · Phase 3 · Dana-Farber Cancer Institute
Dec 2026Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL · Phase 3 · Nanfang Hospital, Southern Medical University
Dec 2026Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) · Phase 3 · Children's Cancer Group, China
Mar 2027Study of Out of Specification for Tisagenlecleucel · Phase 3 · Novartis Pharmaceuticals
Jun 2027Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL · Phase 3 · Shanxi Bethune Hospital
Jun 2027Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies · Phase 3 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Aug 2027An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial · Phase 3 · AbbVie
Sep 2027Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL · Phase 3 · Gruppo Italiano Malattie EMatologiche dell'Adulto
Sep 2027Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia · Phase 3 · Princess Maxima Center for Pediatric Oncology
Oct 2027Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures · Phase 3 · Acacia Pharma Ltd

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger. 247 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 29 (8%) take healthy volunteers.

Recruiting studies that take each age, of 370
Age	Women	Men
10	201 (54%)	201 (54%)
18	329 (89%)	329 (89%)
30	237 (64%)	237 (64%)
40	226 (61%)	226 (61%)
50	218 (59%)	218 (59%)
65	194 (52%)	194 (52%)
75	139 (38%)	139 (38%)
85	105 (28%)	105 (28%)

Across all 2,584 studies, recruiting or not: 57% stop at 75 or younger and 46% at 65; 58% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Precursor Cell Lymphoblastic Leukemia-Lymphoma studies take

Of 227 phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 74 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	55 mo34–90 · 208 studies	49 mo30–65 · 50 studies	57 mo38–92 · 158 studies
Phase 1/2	81 mo56–119 · 114 studies	—	75 mo57–119 · 81 studies
Phase 2	74 mo42–120 · 227 studies	—	79 mo43–120 · 209 studies
Phase 3	86 mo46–104 · 59 studies	—	95 mo65–109 · 43 studies
Phase 4	69 mo27–123 · 30 studies	—	—
Interventional, no phase	32 mo12–66 · 214 studies	—	33 mo12–66 · 207 studies
Observational	54 mo24–142 · 163 studies	—	54 mo26–143 · 145 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting6

Prophylactic DLI-X for Leukemia Relapse After HCTOct 29, 2026NCT07254793
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)Oct 29, 2026NCT07614022
Hospital Based Continuous Patient Monitoring SystemOct 27, 2026NCT06739447
Brain MRF in Children, Adolescents and Young Adults With Acute LeukemiaOct 20, 2026NCT06421155
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLOct 20, 2026NCT07297914

Show 1 more

Phase I Study of FXS0683 in the Treatment of Blood TumorsOct 14, 2026NCT07616089

Show 2 more

Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.Oct 20, 2026NCT07883941
Feasibility and Acceptability of Remote Saliva CollectionOct 20, 2026NCT07884474

Studies

Recruiting first, then most recently updated. Showing 50 of 2,584. Browse all 2,584 → or search them.